The design of the three major CV outcome trials on PCSK9 inhibitors were explained and the results of the FOURIER trial were discussed in detail.

The need for additional therapies to lower LDL-c levels was discussed and subsequently the effect of PCSK9 inhibitors in different studies was explained in several patient populations.

Prof. Chapman briefly introduced the outcome trials on the two PCSK9 inhibitors evolocumab and alirocumab and explained in more detail the pathophysiology of atherosclerotic CVD.

The role of PCSK9 inhibitors as a novel strategy to reduce LDL-c was addressed in this educational program at the ESC Congress 2017 in Barcelona, Spain.

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017